Search

Your search keyword '"Nod2 Signaling Adaptor Protein genetics"' showing total 1,428 results

Search Constraints

Start Over You searched for: Descriptor "Nod2 Signaling Adaptor Protein genetics" Remove constraint Descriptor: "Nod2 Signaling Adaptor Protein genetics"
1,428 results on '"Nod2 Signaling Adaptor Protein genetics"'

Search Results

1. Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series.

2. RIPK2 inhibition gets the NOD for asthma.

3. NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis.

4. Long-Term Visual Outcome of Patients with Blau Syndrome.

5. TNFRSF11A variants contribute to systemic autoinflammatory diseases: A case series of 12 patients.

6. Comprehensive clinical phenotype, genotype and therapy in Yao syndrome.

7. Innate immunity gene Nod2 protects mice from orthotopic breast cancer.

8. The Salmonella Effector SspH2 Facilitates Spatially Selective Ubiquitination of NOD1 to Enhance Inflammatory Signaling.

9. Expanding clinical characteristics and genotypic profiling of Yao syndrome in Chinese patients.

10. CD62-L down-regulation after L18-MDP stimulation as a complementary flow cytometry functional assay for the diagnosis of XIAP deficiency.

11. Molecular diagnostic yield for Blau syndrome in previously diagnosed juvenile idiopathic arthritis with uveitis or cutaneous lesions.

12. Short-peptide-based enteral nutrition affects rats MDP translocation and protects against gut-lung injury via the PepT1-NOD2-beclin-1 pathway in vivo.

13. Proteomic Profiling of Tears in Blau Syndrome Patients in Identification of Potential Disease Biomarkers.

14. Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms.

15. NOD1 and NOD2 genetic variants: Impact on hepatocellular carcinoma susceptibility and progression in Moroccan population.

16. Synergistic Targeting of Innate Receptors TLR7 and NOD2 for Therapeutic Intervention in Multiple Sclerosis.

17. Targeting IL-1 controls refractory pityriasis rubra pilaris.

18. Blau Syndrome: Challenging Molecular Genetic Diagnostics of Autoinflammatory Disease.

19. E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression.

20. Blau Syndrome With Delayed Cutaneous Manifestations: A Case Report.

21. Role and molecular mechanism of NOD2 in chronic non-communicable diseases.

22. LGP2 Facilitates Bacterial Escape through Binding Peptidoglycan via EEK Motif and Suppressing NOD2-RIP2 Axis in Cyprinidae and Xenocyprididae Families.

23. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.

24. Peptidoglycan fragment release and NOD activation by commensal Neisseria species from humans and other animals.

25. Susceptibility of nucleotide-binding oligomerization domain 2 mutations to Whipple's disease.

26. Prognostic value of inflammation and immune-related gene NOD2 in clear cell renal cell carcinoma.

27. Transcription of NOD1 and NOD2 and their interaction with CARD9 and RIPK2 in IFN signaling in a perciform fish, the Chinese perch, Siniperca chuatsi .

28. A Systemic Review and Meta-analysis on Natural Resistance-associated Macrophage Protein 1 (3'-Untranslated Region) and Nucleotide-binding Oligomerization Domain-2 (rs8057341) Polymorphisms and Leprosy Susceptibility in Asian and Caucasian Populations.

29. Identification, characterization and the inflammatory regulating effect of NOD1/2 in sturgeon.

30. Identifying functional dysregulation of NOD2 variant Q902K in patients with Yao syndrome.

31. Novel role of peptidoglycan recognition protein 2 in activating NOD2-NFκB inflammatory axis in coronary artery disease.

32. The expanding clinical spectrum of autoinflammatory diseases with NOD2 variants: a case series and literature review.

35. NOD2 silencing promotes cell apoptosis and inhibits drug resistance in chronic lymphocytic leukemia by inhibiting the NF-κB signaling pathway.

36. NOD2 Polymorphisms May Direct a Crohn Disease Phenotype in Patients With Very Early-Onset Inflammatory Bowel Disease.

37. Synthesis and validation of click-modified NOD1/2 agonists.

38. Implications of combined NOD2 and other gene mutations in autoinflammatory diseases.

39. Loss of NOD2 in macrophages improves colitis and tumorigenesis in a lysozyme-dependent manner.

40. Case Report: Methotrexate and hydroxychloroquine in combination for the treatment of NOD2-mutation-associated Blau syndrome.

41. Presence of NOD2 mutations is not associated with hepatic or systemic hemodynamic abnormalities of cirrhosis.

42. Blau syndrome with NOD2 mutation in a 54-year-old man: A case report.

44. Distinct NOD2 mutations reported in three families with Blau syndrome (BS) from a single center in India - Case series and review of literature.

45. Decoding the IBD paradox: A triadic interplay between REG3, enterococci, and NOD2.

46. Influence of NOD2 risk variants on hepatic encephalopathy and association with inflammation, bacterial translocation and immune activation.

47. Multimorbidity due to novel pathogenic variants in the WFS1/RP1/NOD2 genes: autosomal dominant congenital lamellar cataract, retinitis pigmentosa and Crohn's disease in a British family.

49. A nod to the bond between NOD2 and mycobacteria.

50. Long-term effect of Toll-like receptor-2, -4, -5, -7 and NOD2 stimulation on Na + ,K + -ATPase activity and expression in intestinal epithelial cells.

Catalog

Books, media, physical & digital resources